×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Pharnext blames 'unexpected' placebo results for phase 3 failure
Fierce Biotech
The company is developing PXT3003 in Charcot-Marie-Tooth disease type 1A, an inherited genetic disorder that affects the peripheral nerves,...
4 months ago
Pharnext working toward applications for PXT3003 approval
Charcot-Marie-Tooth News
Pharnext is analyzing clinical trial data that could support applications to approve PXT3003, a therapy candidate for CMT1A.
4 months ago
Pharnext hit again as rare disease drug flunks phase 3 test
Pharmaphorum
Pharnext has been testing PXT3003 (a fixed-dose combination of baclofen, naltrexone and sorbitol) in the pivotal PREMIER trial, which recruited...
4 months ago
Pharnext takes full stock of its operating, strategic and financial situation
Actusnews Wire
Pharnext has a first-in-class drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating,...
1 month ago
Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease…
Actusnews Wire
Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A · PARIS, France, February...
2 months ago
Charcot-Marie-Tooth Disease Market Size and Share to Grow by 2032, Predicts DelveInsight | Key Players in the ...
GlobeNewswire
The increase in the Charcot-Marie-Tooth disease market size is a direct consequence of increasing prevalent population of...
7 months ago
Pharnext announces first patient enrolled in phase 3 study of PXT3003
Labiotech.eu
In the U.S., the first patient has been enrolled in a phase 3 clinical trial of Pharnext's PXT3003 for type 1A Charcot-Marie-Tooth Disease.
19 months ago
Pharnext Announces a €2.5m Loan Agreement with Néovacs
Yahoo Finance
Pharnext SA (FR0011191287-ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics...
20 months ago
How A.I. Is Finding New Cures in Old Drugs
Fortune
Pharma startups like Pharnext are deploying machine learning to search for new therapeutic uses for “off patent” medications.
61 months ago
Pharnext's PXT864 Shows Neuroprotective Effects in ALS, Early...
ALS News Today
PXT864 combines low doses of two repurposed therapies: baclofen, currently used to treat spasticity (stiff, heavy, and difficult-to-move muscles)...
44 months ago